TY - JOUR
T1 - Treatment results of chemoradiotherapy with 5-FU/CDGP for head and neck cancer
AU - Himei, Kengo
AU - Katayama, Norihisa
AU - Takemoto, Mitsuhiro
AU - Kuroda, Masahiro
AU - Kanazawa, Susumu
AU - Nomiya, Shigenobu
AU - Onoda, Tomoo
AU - Tominaga, Susumu
PY - 2006
Y1 - 2006
N2 - We investigated the safety and efficacy of alternative and concurrent chemoradiotherapy with 5-FU/CDGP for head and neck cancer. From January 2003 to August 2005, 19 patients with head and neck squamous cell carcinoma were treated in our institution. Alternative chemoradiotherapy (ACRT) was performed for 8 cases of nasopharyngeal cancer. Concurrent chemoradiotherapy (CCRT) was performed for 11 cases of other head and neck cancer. Median total dose of radiotherapy was 63Gy. ACRT consisted of 5-FU at a dose of 500mg/m2 on days 1-5 and 28-32 and CDGP at a dose of 60mg/m2 on days 6 and 33. CCRT consisted of 5-FU at a dose of 500mg/m2 on days 1-4 and 28-31 and CDGP at a dose of 60mg/m2 on days 5 and 32. Median follow-up periods was 13 months. CR+PR was admitted in five cases (63%) with ACRT, and in 9 cases (82%) with CCRT. Non-hematological adverse effects of grade 3 were admitted in eight cases (100%) of ACRT, and in 9 cases (82%) of CCRT. Chemoradiotherapy attained good results and non-hematological adverse effects were able to be managed by preserved treatment.
AB - We investigated the safety and efficacy of alternative and concurrent chemoradiotherapy with 5-FU/CDGP for head and neck cancer. From January 2003 to August 2005, 19 patients with head and neck squamous cell carcinoma were treated in our institution. Alternative chemoradiotherapy (ACRT) was performed for 8 cases of nasopharyngeal cancer. Concurrent chemoradiotherapy (CCRT) was performed for 11 cases of other head and neck cancer. Median total dose of radiotherapy was 63Gy. ACRT consisted of 5-FU at a dose of 500mg/m2 on days 1-5 and 28-32 and CDGP at a dose of 60mg/m2 on days 6 and 33. CCRT consisted of 5-FU at a dose of 500mg/m2 on days 1-4 and 28-31 and CDGP at a dose of 60mg/m2 on days 5 and 32. Median follow-up periods was 13 months. CR+PR was admitted in five cases (63%) with ACRT, and in 9 cases (82%) with CCRT. Non-hematological adverse effects of grade 3 were admitted in eight cases (100%) of ACRT, and in 9 cases (82%) of CCRT. Chemoradiotherapy attained good results and non-hematological adverse effects were able to be managed by preserved treatment.
KW - alternative chemoradiotherapy
KW - concurrent chemoradiotherapy
KW - head and neck cancer
KW - nasopharyngeal cancer
UR - http://www.scopus.com/inward/record.url?scp=85009580332&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85009580332&partnerID=8YFLogxK
U2 - 10.5981/jjhnc.32.378
DO - 10.5981/jjhnc.32.378
M3 - Article
AN - SCOPUS:85009580332
VL - 32
SP - 378
EP - 383
JO - Japanese Journal of Head and Neck Cancer
JF - Japanese Journal of Head and Neck Cancer
SN - 1349-5747
IS - 3
ER -
